[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"article-CSN-201026119--":3,"related-articles-undefined-undefined-3b0c143a-1ddd-4edc-8eae-c9192ac88aac-true":15},{"id":4,"type":5,"title":6,"pubDate":7,"logoUrl":8,"anpFeedCategory":9,"organisationTitle":10,"thirdParty":11,"body":12,"orgId":13,"description":14},"CSN-201026119","PRESSRELEASE"," Patronus Biotech Receives Ethical Approval to Begin First-in-Human Phase 1 Trial of Three Multi-Stage Vaccines Against Malaria in Australia","2026-10-20T14:51:25.000+02:00","https:\u002F\u002Fwww.persberichten.nl\u002Fimg\u002Fpr-newswire.png","Economie","PR Newswire",true,"\u003Cp> \nBellberry Limited Research Ethics Committee approves first-in-human study in Australia of Patronus Biotech's novel multi-stage virus-like-particle (VLP)-based malaria vaccine candidates targeting Plasmodium falciparum and Plasmodium vivax\u003C\u002Fp>\u003Cp> GUANGZHOU, China, Oct. 20, 2026 \u002FPRNewswire\u002F -- Patronus Biotech, a biotechnology company that develops next-generation vaccines to address unmet global needs, today announced that its Phase I first-in-human clinical trial NCT07831226 of three novel multi-stage VLP-based investigational vaccine candidates for malaria has received ethical approval from Bellberry Limited on 19 October 2026. LYB014 targets 3 key stages of the Plasmodium falciparum malaria parasite lifecycle; LYB017 targets 3 key stages of the Plasmodium vivax malaria parasite lifecycle; and LYB027 targets these 3 key life stages of both the P. falciparum and P. vivax lifecycles. These vaccines will be tested with the proprietary A02 adjuvant, a novel liposomal adjuvant containing fully synthetic active ingredients. The randomised, double-blinded, controlled, dose-escalation trial will evaluate the safety and immunogenicity of these vaccines in healthy adult volunteers at Nucleus Network Pty Ltd., in Melbourne, Australia; with first participant enrolment expected December 2026. The immunogenicity analysis is being conducted in collaboration with the Draper Lab, based at the Department of Paediatrics at the University of Oxford.\u003C\u002Fp>\u003Cp> \nThese vaccines were developed at Patronus Biotech and were designed to address the need for a next-generation vaccine for malaria that can target the three key stages of the malaria life cycle, with the ambition of contributing to future efforts to eliminate malaria by preventing infection, disease and transmission.\u003C\u002Fp>\u003Cp> Despite significant progress, malaria remains a major global health threat causing an estimated 282 million cases and 610,000 deaths in 2024. The two key malaria species accounting for the majority of these cases are P. falciparum and P. vivax. Both have complex life cycles beginning as sporozoites transmitted by the bite of an infected mosquito, where they travel to the liver (1), before emerging into the bloodstream where they invade and replicate within red blood cells (2). A portion of these parasites become the sexual-stage which is then taken up by another mosquito (3) to progress the lifecycle and allow transmission to the next person. The currently WHO-approved RTS,S\u002FAS01 and R21\u002FMatrix-M vaccines target the 1st stage of the P. falciparum parasite lifecycle only and demonstrated partial efficacy against clinical malaria in previous Phase 2\u002F3 field trials in paediatric populations. LYB014\u002F017\u002F027 are designed to test whether additionally targeting the remaining stages of the life-cycle and\u002For targeting multiple parasite species, can provide complementary, layered protection, a hypothesis that will be assessed in future efficacy trials.\u003C\u002Fp>\u003Cp> Simon Draper, Professor of Vaccinology and Translational Medicine at the Department of Paediatrics, said: \"We are pleased to be collaborating with Patronus Biotech on the immunogenicity analysis for this first-in-human study. Malaria remains a major global health challenge, and there is an ongoing need to explore new vaccine approaches that could provide broader protection across different stages of the parasite's life cycle.\"\u003C\u002Fp>\u003Cp> \"Our scientific approach has the potential to transform the fight against malaria,\" said Dr. Jin, Chief Executive Officer of Patronus Biotech. \"Our goal with our malaria vaccines and the A02 adjuvant is not just to prevent infection, but to create a more robust and affordable shield that can combat the parasite's complex biology. This could be a critical step toward eventual malaria elimination.\"\u003C\u002Fp>\u003Cp> Media Contact:Rebecca Dabbs, Chief Alliance \u003Ca target=\"_blank\" href=\"mailto:rebecca.dabbs@patronusbio.com\">Officerrebecca.dabbs@patronusbio.com\u003C\u002Fa>\u003C\u002Fp>\u003Cp> \u003C\u002Fp>\u003Cp> \u003C\u002Fp>\u003Cp>  View original content:https:\u002F\u002Fwww.prnewswire.co.uk\u002Fnews-releases\u002Fpatronus-biotech-receives-ethical-approval-to-begin-first-in-human-phase-1-trial-of-three-multi-stage-vaccines-against-malaria-in-australia-302914071.html\u003C\u002Fp>","3b0c143a-1ddd-4edc-8eae-c9192ac88aac","Bellberry Limited Research Ethics Committee approves first-in-human study in Australia of Patronus Biotech's novel multi-stage virus-like-particle (VLP)-based m",[16,21,26,31,36,37,42,47,52,56],{"id":17,"title":18,"pubDate":19,"logoUrl":8,"thirdParty":11,"orgId":13,"description":20},"CSN-201026159"," New Private Equity gaat partnerschap aan met ONE group solutions voor het bouwen van datagedreven fondsbestuursplatform voor wereldwijde vermogen","2026-10-20T17:27:25.000+02:00","De door CSSF goedgekeurde investering ondersteunt een door de oprichter geleid toonaangevend bedrijf dat jaarlijks met meer dan 35% groeit; ONE zal zijn inspann",{"id":22,"title":23,"pubDate":24,"logoUrl":8,"thirdParty":11,"orgId":13,"description":25},"CSN-201026127"," VikingCloud and Fiserv Expand Strategic Partnership to Deliver Cyber Risk Defense to Merchants","2026-10-20T15:08:25.000+02:00","Multi-Year Agreement Extends Merchant Cybersecurity Protection Across North America and EMEA CHICAGO and DUBLIN, Oct. 20, 2026 \u002FPRNewswire\u002F -- VikingCloud, a cy",{"id":27,"title":28,"pubDate":29,"logoUrl":8,"thirdParty":11,"orgId":13,"description":30},"CSN-201026126"," HNS 2026 | Huawei en brancheorganisaties publiceren in Europa een witboek over hoogwaardige intelligente campusnetwerken van 10 Gbps","2026-10-20T15:07:24.000+02:00","FLORENCE, Italië, 20 oktober 2026 \u002FPRNewswire\u002F -- Tijdens de Huawei Network Summit 2026 (HNS 2026) hebben Huawei en vooraanstaande organisaties en pioniers uit ",{"id":32,"title":33,"pubDate":34,"logoUrl":8,"thirdParty":11,"orgId":13,"description":35},"CSN-201026123"," A1 Becomes More: Antigravity Reveals Three New Ways to Fly, Create, and Explore with A1","2026-10-20T15:03:24.000+02:00","LOS ANGELES, Oct. 20, 2026 \u002FPRNewswire\u002F -- Antigravity today announced three innovations* designed to take its award-winning drone to new heights. - Follow Me B",{"id":4,"title":6,"pubDate":7,"logoUrl":8,"thirdParty":11,"orgId":13,"description":14},{"id":38,"title":39,"pubDate":40,"logoUrl":8,"thirdParty":11,"orgId":13,"description":41},"CSN-201026118"," HNS 2026 | Huawei lanceert de vernieuwde en verbeterde Stellar Intelligent Fabric voor de Europese markt","2026-10-20T14:47:24.000+02:00","FLORENCE, Italië, 20 oktober 2026 \u002FPRNewswire\u002F -- Tijdens de Huawei Network Summit 2026 Europe (HNS 2026) kwamen marktleiders bijeen voor de rondetafelconferent",{"id":43,"title":44,"pubDate":45,"logoUrl":8,"thirdParty":11,"orgId":13,"description":46},"CSN-201026108"," Bitmine Immersion Technologies (BMNR) maakt bekend dat zijn ETH-bezit 6,04 miljoen tokens bedraagt en dat de totale waarde van zijn cryptobezitti","2026-10-20T14:16:24.000+02:00","Bitmine bezit 4,9% van het totale ETH-aanbod van 122,1 miljoen Bitmine heeft in slechts 15 maanden 99% van de weg naar de 'Alchemy of 5%' afgelegd Bitmine publi",{"id":48,"title":49,"pubDate":50,"logoUrl":8,"thirdParty":11,"orgId":13,"description":51},"CSN-201026105"," DJI Osmo Pocket 4P Pearl White Now Available, Bringing Style to Cinematic Creators Worldwide","2026-10-20T14:05:25.000+02:00","The Pearl White Edition of DJI's Breakthrough Dual-Lens Gimbal Camera Offers 17 Stops of Dynamic Range, 10-bit HDR Video, and Advanced D-Log 2 Color Science SHE",{"id":53,"title":54,"pubDate":50,"logoUrl":8,"thirdParty":11,"orgId":13,"description":55},"CSN-201026106"," CAS collaborates with Microsoft to enable faster innovation in pharmaceutical, life sciences, and chemical industries","CAS ConnectionsSM integrates trusted human-curated scientific knowledge into Microsoft Copilot COLUMBUS, Ohio, Oct. 20, 2026 \u002FPRNewswire\u002F -- CAS, a division of ",{"id":57,"title":58,"pubDate":59,"logoUrl":8,"thirdParty":11,"orgId":13,"description":60},"CSN-201026103"," Aliplast (Herambiente Group) inaugurates R3GID in Modena, the new rigid plastics recycling plant","2026-10-20T14:00:24.000+02:00","MODENA, Italy, Oct. 20, 2026 \u002FPRNewswire\u002F -- Aliplast, a Herambiente Group (part of the Hera Group multi-utility) subsidiary and one of Italy's leading companie"]